|
News U.S. Food And Drug Administration Approves Pfizer’s INLYTA (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
-Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) |